@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn

• https://twitter.com/KDAO2011/status/1800889681359642799/photo/1

Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024

Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls. Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids) @RheumNow https://t.co/Fz1dZUVomF

• https://twitter.com/bella_mehta/status/1800888908831674721/photo/1
• https://twitter.com/bella_mehta/status/1800888908831674721/photo/1

Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1
• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1

Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6

• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1
• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1

CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e

• https://twitter.com/drpnash/status/1800878499059622392/photo/1

« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett Are we finally looking at the « visionary scenario »? @RheumNow #EULAR2024 https://t.co/tzfDormeIl

• https://twitter.com/AurelieRheumo/status/1800877955922759712/photo/1

@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate @drdavidliew (NOT in support of regulation) - is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts - is the warning justified? - are there unintended consequences? @RheumNow https://t.co/TXUf90fqwN

• https://twitter.com/Yuz6Yusof/status/1800875811693867070/photo/1
• https://twitter.com/Yuz6Yusof/status/1800875811693867070/photo/1

Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test? @eular_org @Janetbirdope @RheumNow What does #MedTwitter think? https://t.co/bqwPU8XX5S

• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1

Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI

• https://twitter.com/KDAO2011/status/1800873281085710534/photo/1

#EULAR2024 JAK-i Debate. @Janetbirdope [Pro Regulatory Safety Measures] - to do no harm esp since there are other alternatives - supported by RCT - although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg

• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1
• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1

Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa

• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1
• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1

Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

• https://twitter.com/i/web/status/1800870035440775350
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1